CA2918707A1 - Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir et un comprime monolithique comprenant du darunavir et du ritonavir - Google Patents
Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir et un comprime monolithique comprenant du darunavir et du ritonavir Download PDFInfo
- Publication number
- CA2918707A1 CA2918707A1 CA2918707A CA2918707A CA2918707A1 CA 2918707 A1 CA2918707 A1 CA 2918707A1 CA 2918707 A CA2918707 A CA 2918707A CA 2918707 A CA2918707 A CA 2918707A CA 2918707 A1 CA2918707 A1 CA 2918707A1
- Authority
- CA
- Canada
- Prior art keywords
- ritonavir
- darunavir
- tablet
- pharmaceutical formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871674P | 2013-08-29 | 2013-08-29 | |
US61/871,674 | 2013-08-29 | ||
PCT/IB2014/001637 WO2015028875A2 (fr) | 2013-08-29 | 2014-08-28 | Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir et un comprimé monolithique comprenant du darunavir et du ritonavir |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2918707A1 true CA2918707A1 (fr) | 2015-03-05 |
Family
ID=51830545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2918707A Abandoned CA2918707A1 (fr) | 2013-08-29 | 2014-08-28 | Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir et un comprime monolithique comprenant du darunavir et du ritonavir |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3038607A2 (fr) |
AR (1) | AR097512A1 (fr) |
CA (1) | CA2918707A1 (fr) |
HK (1) | HK1220390A1 (fr) |
IL (1) | IL244107A0 (fr) |
MX (1) | MX2016002560A (fr) |
TW (1) | TW201542212A (fr) |
WO (1) | WO2015028875A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015155673A1 (fr) * | 2014-04-08 | 2015-10-15 | Teva Pharmaceutical Industries Ltd | Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir |
CA2937365C (fr) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee |
KR101777564B1 (ko) | 2016-05-30 | 2017-09-12 | 영남대학교 산학협력단 | 테노포비어 디소프록실 유리염기를 함유한 정제 조성물 및 이의 제조방법 |
WO2018153977A1 (fr) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Composition stable de ténofovir alafénamide |
CN108727401A (zh) * | 2017-04-20 | 2018-11-02 | 盐城迪赛诺制药有限公司 | 达鲁那韦新晶型及其制备方法和应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
PT810209E (pt) | 1992-08-25 | 2002-09-30 | Searle & Co | Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
CO5090830A1 (es) | 1998-07-20 | 2001-10-30 | Abbott Lab | Poliformo de un agente farmaceutico |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
ES2308136T3 (es) | 2003-01-14 | 2008-12-01 | Gilead Sciences, Inc. | Composiciones y procedimientos para la politerapia antiviral. |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
WO2006005720A1 (fr) * | 2004-07-08 | 2006-01-19 | Tibotec Pharmaceuticals Ltd. | Combinaison d'inhibiteurs de protease et de tanscriptase inverse anti-vih |
AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
AU2008268537B2 (en) * | 2007-06-22 | 2012-11-01 | Bristol-Myers Squibb Holdings Ireland | Tableted compositions containing atazanavir |
GT200800303A (es) | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
JP2012509320A (ja) * | 2008-11-21 | 2012-04-19 | ウルティモルフィクス・テクノロジーズ・ベー・フェー | テノフォビル、エムトリシタビン及びエファビレンツの湿式造粒法 |
WO2011013110A1 (fr) * | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Formes posologiques unitaires d'inhibiteurs de protéase du vih |
EP2332532A1 (fr) * | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | Nouveaux schémas d'administration de multithérapies utiles pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (vih) |
EP2332544A1 (fr) | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | Nouvelle composition pharmaceutique utile pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (VIH) |
KR101817991B1 (ko) | 2011-07-07 | 2018-01-12 | 얀센 사이언시즈 아일랜드 유씨 | 다루나비어 제제 |
WO2013057469A1 (fr) | 2011-10-20 | 2013-04-25 | Cipla Limited | Compositions pharmaceutiques antirétrovirales |
GB201118182D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
GB201119032D0 (en) * | 2011-11-03 | 2011-12-14 | Isis Innovation | Multisomes: encapsulated droplet networks |
KR20140119177A (ko) * | 2012-02-03 | 2014-10-08 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법 |
US20150045400A1 (en) * | 2012-03-01 | 2015-02-12 | Bandi Parthasaradhi Reddy | Ritonavir compositions |
IN2013MU01749A (fr) * | 2013-05-15 | 2015-06-26 | Cipla Ltd |
-
2014
- 2014-08-28 MX MX2016002560A patent/MX2016002560A/es unknown
- 2014-08-28 CA CA2918707A patent/CA2918707A1/fr not_active Abandoned
- 2014-08-28 WO PCT/IB2014/001637 patent/WO2015028875A2/fr active Application Filing
- 2014-08-28 EP EP14790289.4A patent/EP3038607A2/fr not_active Withdrawn
- 2014-08-29 TW TW103129876A patent/TW201542212A/zh unknown
- 2014-08-29 AR ARP140103253A patent/AR097512A1/es unknown
-
2016
- 2016-02-14 IL IL244107A patent/IL244107A0/en unknown
- 2016-07-19 HK HK16108535.7A patent/HK1220390A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL244107A0 (en) | 2016-04-21 |
WO2015028875A3 (fr) | 2015-11-19 |
MX2016002560A (es) | 2016-10-26 |
AR097512A1 (es) | 2016-03-23 |
TW201542212A (zh) | 2015-11-16 |
WO2015028875A2 (fr) | 2015-03-05 |
WO2015028875A8 (fr) | 2016-09-01 |
EP3038607A2 (fr) | 2016-07-06 |
HK1220390A1 (zh) | 2017-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2942877A1 (fr) | Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir | |
US11819577B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
US10105365B2 (en) | Solid antiviral dosage forms | |
CA2918707A1 (fr) | Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir et un comprime monolithique comprenant du darunavir et du ritonavir | |
CA2713365A1 (fr) | Composition a liberation prolongee stabilisee a base de chlorhydrate de bupropion et procede de preparation de cette composition | |
JP2014196334A (ja) | クエチアピンを含む徐放性医薬組成物 | |
CA3006192C (fr) | Compositions pharmaceutiques contenant de la doravirine, du fumarate de tenofovir disoproxil et de la lamivudine | |
WO2017208136A1 (fr) | Composition pharmaceutique de co-cristal de dapagliflozine | |
US20160199396A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
US20220362235A1 (en) | Pharmaceutical compositions of cabozantinib | |
US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
US20140343076A1 (en) | Pharmaceutical compositions of lurasidone | |
US11679105B1 (en) | Pharmaceutical compositions of cabozantinib | |
EP3886817A1 (fr) | Composition pharmaceutique comprenant du ramipril et de l'indapamide | |
WO2022153330A1 (fr) | Compositions pharmaceutiques comprenant de l'acalabrutinib | |
WO2017029226A1 (fr) | Composition pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz | |
AU2014295098B2 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
JP2015516971A (ja) | ざ瘡の処置方法 | |
WO2024084496A1 (fr) | Compositions pharmaceutiques comprenant du maléate d'acalabrutinib | |
TW202224681A (zh) | 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物 | |
KR20150055986A (ko) | 보센탄 제어방출성 경구제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20180828 |